Hidradenitis Suppurativa Phase 2b Study of Izokibep

Summary

Izokibep is a potent and selective inhibitor of interleukin 17A (IL-17A) that is being developed for treatment of hidradenitis suppurativa (HS). This study will evaluate the efficacy, safety, and immunogenicity of izokibep administered subcutaneously (SC) in adult subjects with moderate to severe HS.

Timeline

Start

2022-05-05

Primary completion

2023-08-02

Completion

2024-02-21

Drugs

Indications